News headlines about Natus Medical (NASDAQ:BABY) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Natus Medical earned a news impact score of 0.12 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 45.5598265787024 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Natus Medical (BABY) traded up $0.70 during mid-day trading on Monday, hitting $33.30. The stock had a trading volume of 30,068 shares, compared to its average volume of 595,388. The firm has a market capitalization of $1,081.03, a PE ratio of -53.14 and a beta of 0.55. The company has a current ratio of 3.32, a quick ratio of 2.54 and a debt-to-equity ratio of 0.37. Natus Medical has a 12 month low of $28.00 and a 12 month high of $43.60.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.54 by ($0.12). The company had revenue of $131.40 million during the quarter, compared to analyst estimates of $131.38 million. Natus Medical had a negative net margin of 4.05% and a positive return on equity of 11.36%. The company’s quarterly revenue was up 22.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.51 EPS. equities analysts forecast that Natus Medical will post 1.63 earnings per share for the current year.
BABY has been the subject of a number of recent research reports. BidaskClub cut Natus Medical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 6th. Zacks Investment Research cut Natus Medical from a “hold” rating to a “strong sell” rating in a report on Thursday, January 11th. Benchmark reaffirmed a “buy” rating and issued a $49.00 target price (down previously from $55.00) on shares of Natus Medical in a report on Tuesday, January 16th. William Blair cut Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Finally, Roth Capital set a $39.00 target price on Natus Medical and gave the stock a “buy” rating in a report on Tuesday, February 27th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. Natus Medical presently has an average rating of “Hold” and a consensus target price of $44.33.
In other news, Director Ken Ludlum sold 4,000 shares of the stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $31.68, for a total value of $126,720.00. Following the completion of the sale, the director now owns 93,825 shares of the company’s stock, valued at $2,972,376. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 5.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3257186/natus-medical-baby-given-news-impact-score-of-0-12.html.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.